Schenkein David P — SEC Form 4 filings

SEC reporting owner CIK 1578200. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-08.

Transaction summary — filings shown

Covers all 14 filings on record, filed 2024-02-27 to 2026-06-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
AGIOS PHARMACEUTICALS, INC. (AGIO)Director44 legs · 137,471 sh · $4,658,54312
Denali Therapeutics Inc. (DNLI)Director42 legs · 59,441 sh · $1,932,6658
Prime Medicine, Inc. (PRME)Director47
REGENERON PHARMACEUTICALS, INC. (REGN)Director24

Form 4 filings — Schenkein David P

FiledFormIssuerReported transactionsSource
2026-06-084Prime Medicine, Inc. (PRME)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2026-06-054Denali Therapeutics Inc. (DNLI)Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-01-064REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2025-08-054Prime Medicine, Inc. (PRME)Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative)EDGAR
2025-06-054Prime Medicine, Inc. (PRME)Grant/award (A): 55,000 (derivative) @ $0EDGAR
2025-06-054Denali Therapeutics Inc. (DNLI)Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-01-064REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 166 @ $0 · Grant/award (A): 1,958 (derivative) @ $0EDGAR
2024-11-134Denali Therapeutics Inc. (DNLI)Option exercise (M): 47,165 @ $18 · Sale (S): 27,129 @ $32.09 · Sale (S): 32,312 @ $32.87 · Option exercise (M): 47,165 (derivative) @ $0EDGAR
2024-06-244AGIOS PHARMACEUTICALS, INC. (AGIO)Grant/award (A): 2,120 (derivative) @ $0 · Grant/award (A): 11,774 (derivative) @ $0EDGAR
2024-06-174AGIOS PHARMACEUTICALS, INC. (AGIO)Option exercise (M): 3,388 @ $0 · Option exercise (M): 3,388 (derivative) @ $0EDGAR
2024-06-144Prime Medicine, Inc. (PRME)Grant/award (A): 45,000 (derivative) @ $0EDGAR
2024-06-044Denali Therapeutics Inc. (DNLI)Grant/award (A): 5,967 @ $0 · Grant/award (A): 17,901 (derivative) @ $0EDGAR
2024-02-294AGIOS PHARMACEUTICALS, INC. (AGIO)Option exercise (M): 11,858 @ $31.64 · Sale (S): 11,858 @ $33.60 · Option exercise (M): 57,471 @ $31.64 · Sale (S): 57,471 @ $34.89 · Option exercise (M): 11,858 (derivative) @ $0 · Option exercise (M): 57,471 (derivative) @ $0EDGAR
2024-02-274AGIOS PHARMACEUTICALS, INC. (AGIO)Option exercise (M): 47,731 @ $31.64 · Sale (S): 47,731 @ $33.05 · Option exercise (M): 20,411 @ $31.64 · Sale (S): 20,411 @ $33.19 · Option exercise (M): 47,731 (derivative) @ $0 · Option exercise (M): 20,411 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1578200 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →